Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

Presentation TCT 2019

Transcutaneous Pericardictomy for HFpEF

Presenter: Samuel Asirvatham

September 28, 2019

Presentation TCT 2019

Corvia for HFpEF

Presenter: Scott Lilly

September 28, 2019

Presentation TCT 2019

V-Wave for HFrEF and HFpEF

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

State of the Art: Latest Insights into the Pathophysiology and Medical and Device-Based Therapies for HFpEF

Presenter: Peter Carson

September 28, 2019

Presentation TCT 2019

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Presenter: Felix Mahfoud

September 27, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

L.A. McKeown

April 23, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Shelley Wood

February 26, 2019

Advertisement

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Transcutaneous Pericardictomy for HFpEF

Corvia for HFpEF

V-Wave for HFrEF and HFpEF

State of the Art: Latest Insights into the Pathophysiology and Medical and Device-Based Therapies for HFpEF

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content